SMITH & NEPHEW PLC

Smith+Nephew announced the publication of new consensus-based guidance for single-use negative pressure wound therapy (sNPWT) in closed surgical incisions, developed by expert clinicians and published in "Die Chirurgie." The guidance, supported by Smith+Nephew, highlights that prophylactic sNPWT not only improves clinical outcomes but also positively impacts key economic and operational indicators. It recommends targeted use of sNPWT, such as with the PICO™7 system, in high-risk patients, noting that wound complications significantly increase healthcare costs and patient length of stay.

Smith+Nephew announced the publication of new consensus-based guidance for the use of single-use negative pressure wound therapy (sNPWT) in closed surgical incisions. Developed by expert clinicians and supported by Smith+Nephew, the guidance provides a practical framework for post-surgical care in Germany, highlighting the importance of preventative strategies. It recommends sNPWT for at-risk patients and defines clear treatment boundaries, reinforcing the clinical benefits and features of the company's PICO™7 sNPWT system.

Smith & Nephew plc has applied to the London Stock Exchange for the admission of 150,000 ordinary shares to trading. These shares are reserved under a block admission and will be issued to settle awards under the company's employee share plans. Admission to trading is expected on July 6, 2026, and the new shares will rank equally with existing ordinary shares.

Smith & Nephew plc reported its total voting rights and capital as of June 30, 2026. The company's total issued share capital comprises 877,733,750 ordinary shares, with 32,697,503 shares held in treasury. Consequently, the total number of ordinary shares with voting rights is 845,036,247, which shareholders should use for disclosure purposes.

Cevian Capital II G.P. Limited has notified Smith & Nephew plc of an increase in its shareholding. As of June 12, 2026, the aggregate voting rights held by Cevian Capital II G.P. Limited reached 12.235936%, amounting to 103,717,469 voting rights. This increase is attributed to higher holdings through its managed funds, Cevian Capital II Master Fund L.P. and Cevian Capital II Co-Investment - Series P L.P. The filing clarifies that Cevian Capital II G.P. Limited did not cross a new notification threshold despite the increase. Aurora Nominees Limited acts as the nominee shareholder.

Smith+Nephew announced the successful completion of the first clinical cases using its next-generation CORI XT Handheld Robotics Platform. This marks a significant milestone in the clinical introduction of the technology, which is designed to be a single platform for various orthopedic needs, including knee and shoulder arthroplasty, with future hip indications under development. The initial cases, performed by leading surgeons across hospital and ambulatory surgery center settings, demonstrated the platform's streamlined workflow, seamless planning, and enhanced accuracy, supporting surgeon expertise and efficient procedures.

Smith & Nephew plc announced that its Director and Persons Discharging Managerial Responsibilities (PDMRs) acquired American Depositary Shares (ADS) through the Company's Employee Stock Purchase Plan. These shares were purchased via the Dividend Re-Investment Plan following the 2025 final dividend payment. The transactions took place on June 3, 2026, on the New York Stock Exchange.

Smith & Nephew plc announced transactions by Persons Discharging Managerial Responsibility (PDMRs) and Directors. Several key executives, including the CEO, CFO, and Presidents of Global Operations and Sports Medicine, purchased ordinary shares through the Company's Dividend Re-Investment Plan following the 2025 final dividend payment on May 27, 2026. The transactions occurred on the London Stock Exchange at a price of $11.38002 per share.

Smith & Nephew plc announced the admission of EUR 500,000,000 of 4.250% Notes due June 3, 2038, to trading on the Main Market of the London Stock Exchange. These debt securities were issued under the company's U.S.$5,000,000,000 Euro Medium Term Note Programme. The admission to trading occurred on June 3, 2026, following the base prospectus dated March 17, 2026, and a supplemental prospectus dated May 15, 2026.

Smith+Nephew announced the US launch of its next-generation LEAF Patient Monitoring System, a data-driven platform designed to prevent hospital-acquired pressure injuries (HAPIs). The system uses a wearable sensor to monitor patient mobility, providing real-time turn status updates to improve workflow, turn quality, and protocol adherence. This cloud-hosted solution integrates with hospital EMRs, helping to reduce HAPIs by up to 73% and delivering up to $1.8 million in estimated savings in one critical care facility, addressing the $26.8 billion annual burden of HAPIs in the US.